We are live on ! Find out more
OCA

Octagon Capital Advisors Portfolio holdings

AUM $904M
1-Year Est. Return 737.04%
This Fund
S&P 500
This Quarter Est. Return
-14.68%
1 Year Est. Return
+737.04%
3 Year Est. Return
+2,554.78%
5 Year Est. Return
+4,333.84%
10 Year Est. Return
–
AUM
$463M
AUM Growth
-$51.3M
Cap. Flow
+$47.3M
Cap. Flow %
10.24%
Top 10 Hldgs %
79.39%
Holding
31
New
3
Increased
8
Reduced
6
Closed
7

Top Buys

Rank Stock Value
1
APLS
Apellis Pharmaceuticals
APLS
+$14.1M
2
RCUS icon
Arcus Biosciences
RCUS
+$13.2M
3
KDNY
Chinook Therapeutics, Inc. Common Stock
KDNY
+$11.6M
4
GOSS icon
Gossamer Bio
GOSS
+$10.1M
5
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$9.75M

Top Sells

Rank Stock Value
1
CTKB icon
Cytek Biosciences
CTKB
+$6.53M
2
CRDF icon
Cardiff Oncology
CRDF
+$5.91M
3
RXDX
Prometheus Biosciences, Inc. Common Stock
RXDX
+$4.74M
4
MLTX icon
MoonLake Immunotherapeutics
MLTX
+$3.96M
5
GLUE icon
Monte Rosa Therapeutics
GLUE
+$3.06M

Sector Composition

Rank Sector Weight
1 Healthcare 98.92%
2 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
APLS
1
DELISTED
Apellis Pharmaceuticals
APLS
$119M 25.7%
2,340,059
+319,148
+16% +$14.1M
RCUS icon
2
Arcus Biosciences
RCUS
$3.57B
$78.6M 16.99%
2,489,974
+394,743
+19% +$13.2M
CLDX icon
3
Celldex Therapeutics
CLDX
$2.77B
$25.9M 5.61%
761,398
– –
FDMT icon
4
4D Molecular Therapeutics
FDMT
$526M
$23.7M 5.12%
1,566,895
+15,825
+1% +$249K
BBIO icon
5
BridgeBio Pharma
BBIO
$16.5B
$23M 4.98%
2,267,486
+500,000
+28% +$5.13M
GOSS icon
6
Gossamer Bio
GOSS
$66.5M
$22.2M 4.81%
2,563,138
+1,050,000
+69% +$10.1M
KDNY
7
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$22.2M 4.8%
1,356,250
+856,250
+171% +$11.6M
KROS icon
8
Keros Therapeutics
KROS
$199M
$18.5M 4%
340,214
– –
STOK icon
9
Stoke Therapeutics
STOK
$1.82B
$17.1M 3.7%
813,456
+29,687
+4% +$594K
NBP
10
NovaBridge Biosciences American Depositary Shares
NBP
$205M
$17M 3.69%
1,049,691
– –
ITOS
11
DELISTED
iTeos Therapeutics
ITOS
$14.5M 3.14%
450,776
– –
VERA icon
12
Vera Therapeutics
VERA
$2.54B
$13.5M 2.92%
575,000
-95,940
-14% -$2.06M
ARVN icon
13
Arvinas
ARVN
$518M
$12M 2.6%
178,500
– –
HZNP
14
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$10.5M 2.27%
+100,000
New +$9.75M
IPSC icon
15
Century Therapeutics
IPSC
$381M
$8.29M 1.79%
658,266
-44,357
-6% -$588K
IMVT icon
16
Immunovant
IMVT
$8.09B
$8.13M 1.76%
1,475,000
+902,138
+157% +$5.62M
SURF
17
DELISTED
Surface Oncology, Inc. Common Stock
SURF
$6.76M 1.46%
+2,300,000
New +$8.06M
RNAM
18
DELISTED
Avidity Biosciences
RNAM
$5.94M 1.28%
321,641
-125,000
-28% -$2.12M
DYN icon
19
Dyne Therapeutics
DYN
$4.04B
$5.06M 1.09%
525,284
-58,365
-10% -$497K
XBI icon
20
State Street SPDR S&P Biotech ETF
XBI
$10.1B
$5.01M 1.08%
+55,800
New +$5.15M
RXDX
21
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
$3.02M 0.65%
80,000
-120,000
-60% -$4.74M
OMGA
22
DELISTED
Omega Therapeutics, Inc. Common Stock
OMGA
$1.1M 0.24%
176,470
– –
CNTB
23
Connect Biopharma Holdings
CNTB
$135M
$845K 0.18%
279,921
– –
AMAM
24
DELISTED
Ambrx Biopharma Inc
AMAM
$616K 0.13%
149,400
-187,468
-56% -$959K
CMPX icon
25
Compass Therapeutics
CMPX
$373M
– –
-240,000
Closed -$761K
1
2

Similar funds

AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
AOWM
Asset One Wealth Management Bellevue, Washington $904M AUM
SWM
Sendero Wealth Management San Antonio, Texas $904M AUM 22.78% 1-Year Est. Return
EI
EnCap Investments Houston, Texas $905M AUM
PIP
Permian Investment Partners Dallas, Texas $905M AUM 13.43% 1-Year Est. Return
PSCM
Per Stirling Capital Management Austin, Texas $905M AUM 17.06% 1-Year Est. Return
EWM
Evermay Wealth Management Arlington, Virginia $902M AUM 14.76% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return

Octagon Capital Advisors's Q1 2022 Portfolio in Review

As of Q1 2022, Octagon Capital Advisors held 31 positions worth $463M, down 10% from $514M the previous quarter. Its ten largest holdings account for 79% of the portfolio.

Octagon Capital Advisors deployed $47.3M of net new capital in Q1 2022, opening 3 new positions and adding to 8 existing holdings. Its largest new stake was Horizon Therapeutics Public Limited Company Ordinary Shares: 100,000 shares worth $10.5M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 99% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Prometheus Biosciences, Inc. Common Stock, an estimated $4.74M trimmed.

  • Octagon Capital Advisors's largest Q1 2022 buy was Horizon Therapeutics Public Limited Company Ordinary Shares: 100,000 shares worth $10.5M.
  • Octagon Capital Advisors added most to Apellis Pharmaceuticals in Q1 2022, an estimated $14.1M increase.
  • Octagon Capital Advisors's biggest Q1 2022 reduction was Prometheus Biosciences, Inc. Common Stock, cutting an estimated $4.74M.
  • Octagon Capital Advisors fully exited Cytek Biosciences in Q1 2022, selling an estimated $6.53M.
  • Octagon Capital Advisors's ten largest holdings make up 79% of its $463M portfolio in Q1 2022.
  • Octagon Capital Advisors opened 3 new positions and closed 7 in Q1 2022.
  • Octagon Capital Advisors's portfolio value fell 10% quarter-over-quarter to $463M.

Based on Octagon Capital Advisors's 13F filing for Q1 2022, filed 16 May 2022.